Active substance
Naproxen
- SFDA 14
- US FDA 85
- Health Canada 30
- US price lines 21
- NHS prices 8
- WHO EML 1
- Safety 11
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ALEVE 220 mg film-coated tablet | 220 mg | Film-coated tablet · Oral use | 12 Blister | SAR 11.65 | NCE · OTC | BAYER CONSUMER CARE AG | Valid |
| NAPROTEX 500 mg tablet | 500 mg | Tablet · Oral use | 10 Blister | SAR 18.90 | Generic · OTC | APOTEX | Valid |
| NAPROX 250MG TAB | 250 mg | Tablet · Oral use | 20 Blister | SAR 17.25 | Generic · OTC | Hikma Pharmaceuticals PLC | Valid |
| NAPROX D.S 500MG TAB | 500 mg | Tablet · Oral use | 10 Blister | SAR 14.95 | Generic · OTC | Hikma Pharmaceuticals PLC | Valid |
| PROXEN F.C TAB 500MG | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 35.30 | Generic · OTC | STADA ARZNEIMITTEL GmbH | Valid |
| PROXEN F.C. TAB 250MG | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 26.35 | NCE · OTC | STADA ARZNEIMITTEL GmbH | Valid |
| MIRANAX 550 MG F- C TABLETS | 550 mg | Film-coated tablet · Oral use | 10 Blister | SAR 20.15 | Generic · OTC | GRUNENTHAL | Withdrawn by MAH · Not Marketed |
| NAPROTEX 250MG-TAB. | 250 mg | Tablet · Oral use | 20 Blister | SAR 20.55 | Generic · OTC | APOTEX | Withdrawn by MAH · Not Marketed |
| PROXEN F.C TAB 500MG | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 44.15 | Generic · OTC | GRUNENTHAL | Withdrawn by MAH · Not Marketed |
| PROXEN F.C. TAB 250MG | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 33.00 | NCE · OTC | GRUNENTHAL | Withdrawn by MAH · Not Marketed |
| PROXEPAIN | 220 mg | Film-coated tablet · Oral use | 20 Blister | SAR 19.45 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| PROXEPAIN | 220 mg | Film-coated tablet · Oral use | 10 Blister | SAR 11.05 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIAPROXEN 250 mg film-coated tablet | 250 mg | Film-coated tablet · Oral use | 20 Blister | SAR 22.45 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIAPROXEN 500 mg film-coated tablet | 500 mg | Film-coated tablet · Oral use | 20 Blister | SAR 28.35 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE COUGH; ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; CHRONIC PANCREATITIS; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; EPIDERMOLYSIS BULLOSA; GOUT; INFECTIOUS MONONUCLEOSIS; JUVENILE IDIOPATHIC ARTHRITIS (JIA); LOW BACK PAIN; MENSTRUAL DISORDERS; MIGRAINE/ HEADACHE; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; NECROTIZING PERIODONTITIS AND NECROTIZING ULCERATIVE GINGIVITIS; NON-INFECTIOUS UVEITIS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; PERICORONITIS; PHARYNGITIS; POLYCYTHEMIA VERA - BONE PAIN; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NAPROSYN | 500MG | tablet · oral | ATNAHS PHARMA US | Prescription | 11 Mar 1976 |
| ANAPROX DS | EQ 500MG BASE | tablet · oral | ATNAHS PHARMA US | Prescription | 4 Sep 1980 |
| NAPROSYN | 25MG/ML | suspension · oral | ATNAHS PHARMA US | Prescription | 23 Mar 1987 |
| NAPROXEN | 250MG; 375MG; 500MG | tablet · oral | GRANULES | Prescription | 21 Dec 1993 |
| NAPROXEN | 250MG; 375MG; 500MG | tablet · oral | TEVA | Prescription | 21 Dec 1993 |
| ALEVE | 220MG | tablet · oral | BAYER | Over-the-counter | 11 Jan 1994 |
| NAPROXEN | 25MG/ML | suspension · oral | HIKMA PHARMS | Prescription | 30 Mar 1994 |
| EC-NAPROSYN | 375MG; 500MG | tablet, delayed release · oral | ATNAHS PHARMA US | Prescription | 14 Oct 1994 |
| NAPRELAN | EQ 375MG BASE; EQ 500MG BASE; EQ 750MG BASE | tablet, extended release · oral | TWI PHARMS | Prescription | 5 Jan 1996 |
| NAPROXEN SODIUM | 220MG | tablet · oral | CONTRACT PHARMACAL | Over-the-counter | 13 Jan 1997 |
| NAPROXEN SODIUM | 220MG | tablet · oral | PERRIGO | Over-the-counter | 13 Jan 1997 |
| NAPROXEN | 375MG; 500MG | tablet, delayed release · oral | TEVA | Prescription | 30 Jun 1998 |
| NAPROXEN SODIUM | 220MG | tablet · oral | DR REDDYS LABS INC | Over-the-counter | 28 Jul 1998 |
| NAPROXEN | 375MG; 500MG | tablet, delayed release · oral | AUROBINDO PHARMA USA | Prescription | 19 Apr 2001 |
| NAPROXEN | 250MG; 375MG; 500MG | tablet · oral | AMNEAL PHARMS NY | Prescription | 18 Dec 2001 |
| NAPROXEN SODIUM | EQ 500MG BASE; EQ 375MG BASE; EQ 750MG BASE | tablet, extended release · oral | ACTAVIS LABS FL INC | Prescription | 27 Aug 2002 |
| NAPROXEN SODIUM | EQ 200MG BASE | capsule · oral | BIONPHARMA | Over-the-counter | 17 Feb 2006 |
| NAPROXEN | 250MG; 375MG; 500MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 28 Mar 2007 |
| NAPROXEN SODIUM | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | GLENMARK PHARMS LTD | Prescription | 27 Apr 2007 |
| NAPROXEN | 250MG; 375MG; 500MG | tablet · oral | ZYDUS PHARMS USA | Prescription | 7 Jun 2007 |
| NAPROXEN SODIUM | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | DR REDDYS LABS LTD | Prescription | 26 Jul 2007 |
| NAPROXEN SODIUM | 220MG | tablet · oral | AMNEAL PHARMS NY | Over-the-counter | 16 Dec 2008 |
| NAPROXEN | 250MG; 375MG; 500MG | tablet · oral | MARKSANS PHARMA | Prescription | 14 Feb 2011 |
| NAPROXEN SODIUM | 220MG | tablet · oral | MARKSANS PHARMA | Over-the-counter | 16 Mar 2011 |
| NAPROXEN | 375MG; 500MG | tablet, delayed release · oral | NUVO PHARMS INC | Prescription | 19 Sep 2011 |
60 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ALEVE BACK AND BODY PAIN | 02436337 | 220 MG | CAPSULE · ORAL | BAYER INC |
| ALEVE CAPLETS | 02301733 | 220 MG | TABLET · ORAL | BAYER INC |
| ALEVE LIQUID GELS | 02361795 | 220 MG | CAPSULE · ORAL | BAYER INC |
| ANAPROX | 02162725 | 275 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| ANAPROX DS | 02162717 | 550 MG | TABLET · ORAL | SEARCHLIGHT PHARMA INC |
| APO-NAPRO-NA | 00784354 | 275 MG | TABLET · ORAL | APOTEX INC |
| APO-NAPRO-NA DS | 01940309 | 550 MG | TABLET · ORAL | APOTEX INC |
| APO-NAPROXEN | 00522651 | 250 MG | TABLET · ORAL | APOTEX INC |
| APO-NAPROXEN | 00592277 | 500 MG | TABLET · ORAL | APOTEX INC |
| APO-NAPROXEN | 00600806 | 375 MG | TABLET · ORAL | APOTEX INC |
| APO-NAPROXEN EC | 02246700 | 375 MG | TABLET (ENTERIC-COATED) · ORAL | APOTEX INC |
| APO-NAPROXEN EC | 02246701 | 500 MG | TABLET (ENTERIC-COATED) · ORAL | APOTEX INC |
| APO-NAPROXEN EC TABLETS | 02246699 | 250 MG | TABLET (ENTERIC-COATED) · ORAL | APOTEX INC |
| MAXIDOL LIQUID GELS | 02372991 | 220 MG | CAPSULE · ORAL | BAYER INC |
| NAPROSYN | 02162423 | 500 MG | TABLET (DELAYED-RELEASE) · ORAL | SEARCHLIGHT PHARMA INC |
| NAPROSYN | 02162466 | 750 MG | TABLET (EXTENDED-RELEASE) · ORAL | SEARCHLIGHT PHARMA INC |
| NAPROXEN | 02362430 | 220 MG | TABLET · ORAL | PHARMASCIENCE INC |
| NAPROXEN MENSTRUAL PAIN RELIEF | 02396009 | 220 MG | TABLET · ORAL | PHARMASCIENCE INC |
| NAPROXEN-NA | 00887056 | 275 MG | TABLET · ORAL | PRO DOC LIMITEE |
| NAPROXEN-NA DF | 02153386 | 550 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PEDIAPHARM NAPROXEN SUSPENSION | 02162431 | 25 MG / ML | SUSPENSION · ORAL | MEDEXUS PHARMACEUTICALS INC. |
| PRO-NAPROXEN EC | 02310953 | 500 MG | TABLET (DELAYED-RELEASE) · ORAL | PRO DOC LIMITEE |
| TEVA-NAPROXEN | 00565350 | 250 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-NAPROXEN | 00589861 | 500 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-NAPROXEN | 00627097 | 375 MG | TABLET · ORAL | TEVA CANADA LIMITED |
5 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FT NAPROXEN SODIUM 220 MG CAP | $0.14941 | per EA | 23 Sep 2026 |
| US NADAC | GNP NAPROXEN SOD 220 MG CAPLET | $0.06732 | per EA | 23 Sep 2026 |
| US NADAC | GNP NAPROXEN SOD 220 MG TABLET | $0.06732 | per EA | 23 Sep 2026 |
| US NADAC | GNP NAPROXEN SODIUM 220 MG CAP | $0.14941 | per EA | 23 Sep 2026 |
| US NADAC | GS NAPROXEN SOD 220 MG CAPLET | $0.06732 | per EA | 23 Sep 2026 |
| US NADAC | GS NAPROXEN SOD 220 MG TABLET | $0.06732 | per EA | 23 Sep 2026 |
| US NADAC | NAPROXEN 125 MG/5 ML SUSPEN | $0.20183 | per ML | 23 Sep 2026 |
| US NADAC | NAPROXEN 125 MG/5 ML SUSPEN | $0.12157 | per ML | 23 Sep 2026 |
| US NADAC | NAPROXEN 250 MG TABLET | $0.04356 | per EA | 23 Sep 2026 |
| US NADAC | NAPROXEN 375 MG TABLET | $0.05884 | per EA | 23 Sep 2026 |
| US NADAC | NAPROXEN 500 MG TABLET | $0.05654 | per EA | 23 Sep 2026 |
| US NADAC | NAPROXEN DR 375 MG TABLET | $2.23429 | per EA | 30 Sep 2026 |
| NHS Drug Tariff | Naproxen 125mg/5ml oral suspension sugar free | £110.00 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 250mg effervescent tablets sugar free | £52.72 | 20 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 250mg gastro-resistant tablets | £3.86 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 250mg tablets | £0.96 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 250mg/5ml oral suspension | £90.00 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 375mg gastro-resistant tablets | £7.21 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 500mg gastro-resistant tablets | £12.35 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Naproxen 500mg tablets | £1.35 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.1.5.1. Medicines for acute migraine attacks · core
Therapeutic equivalent to ibuprofen for Migraine
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2024 ANAPROX — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 EC-NAPROSYN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 NAPRELAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 NAPROSYN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 NAPROSYN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 TREXIMET — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 VIMOVO — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 11 Jul 2023 ALEVE-D SINUS & COLD — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 10 Mar 2022 ALEVE — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 8 Feb 2022 ALEVE PM — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 13 Dec 2021 NAPROXEN SODIUM — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Combinations containing Naproxen
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.